Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

During the Combination Therapy Period, the safety and preliminary anti-tumor activity of selinexor in combination with docetaxel (for patients with NSCLC) or pembrolizumab (for patients with CRC) will be evaluated.

kras
fluorouracil
folfiri regimen
metastatic nsclc
carcinoma
  • 0 views
  • 19 Feb, 2024
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A tolerable safety profile and demonstrated efficacy would support a potential, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

transitional cell carcinoma of bladder
intravesical bcg
bladder cancer
transurethral resection
hormone levels
  • 0 views
  • 19 Feb, 2024
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); …

  • 0 views
  • 19 Feb, 2024
Combination Immunotherapy Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines …

immunosuppression
recurrent sarcoma
creatinine clearance rate
renal function
steroid hormone
  • 0 views
  • 19 Feb, 2024
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

hba1c
immunomodulators
g-csf
immune checkpoint inhibitor
menstrual period
  • 0 views
  • 19 Feb, 2024